Related CAS #
87234-24-0 (cinnamate); 85056-47-9 (olamine); 36322-90-4 (free base); 96684-40-1 (betadex)
Synonym
Piroxicam cinnamate; SPA-S-510
IUPAC/Chemical Name
2-methyl-1,1-dioxido-3-(pyridin-2-ylcarbamoyl)-2H-benzo[e][1,2]thiazin-4-yl cinnamate
InChi Key
GPUVGQIASQNZET-CCEZHUSRSA-N
InChi Code
InChI=1S/C24H19N3O5S/c1-27-22(24(29)26-20-13-7-8-16-25-20)23(18-11-5-6-12-19(18)33(27,30)31)32-21(28)15-14-17-9-3-2-4-10-17/h2-16H,1H3,(H,25,26,29)/b15-14+
SMILES Code
CN1C(C(Nc2ncccc2)=O)=C(c3c(S1(=O)=O)cccc3)OC(/C=C/c4ccccc4)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
461.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ficarra R, Villari A, Micali N, Tommasini S, Calabrò ML, Di Bella MR, Melardi S, Agresta MF, Coppolino S, Stancanelli R. Stability study of piroxicam and cinnoxicam in solid pharmaceuticals. J Pharm Biomed Anal. 1999 Jun;20(1-2):283-8. doi: 10.1016/s0731-7085(99)00037-0. PMID: 10704033.
2: Cini R, Tamasi G, Defazio S, Hursthouse MB. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex. J Inorg Biochem. 2007 Aug;101(8):1140-52. doi: 10.1016/j.jinorgbio.2007.04.015. Epub 2007 May 10. PMID: 17592742.
3: Bertè F, Richelmi P. Farmacologia clinica dei farmaci antinfiammatori non steroidei. Un nuovo derivato benzotiazinico: il cinnoxicam [Clinical pharmacology of non-steroidal anti-inflammatory drugs. A new benzothiazine derivative: cinnoxicam]. Minerva Med. 1988 Sep;79(9):811-30. Italian. PMID: 3050617.
4: Cavallini G, Biagiotti G, Ferraretti AP, Gianaroli L, Vitali G. Medical therapy of oligoasthenospermia associated with left varicocele. BJU Int. 2003 Apr;91(6):513-8. doi: 10.1046/j.1464-410x.2003.04136.x. PMID: 12656905.
5: Valsecchi R, Pansera B, Di Landro A, Cainelli T. Contact allergy to cinnoxicam. Contact Dermatitis. 1995 Jan;32(1):63. doi: 10.1111/j.1600-0536.1995.tb00857.x. PMID: 7720389.
6: Cavallini G, Ferraretti AP, Gianaroli L, Biagiotti G, Vitali G. Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele- associated oligoasthenospermia. J Androl. 2004 Sep-Oct;25(5):761-70; discussion 771-2. doi: 10.1002/j.1939-4640.2004.tb02853.x. PMID: 15292108.
7: Cavallini G, Magli MC, Crippa A, Ferraretti AP, Gianaroli L. Reduction in sperm aneuploidy levels in severe oligoasthenoteratospermic patients after medical therapy: a preliminary report. Asian J Androl. 2012 Jul;14(4):591-8. doi: 10.1038/aja.2012.23. Epub 2012 Apr 30. PMID: 22543677; PMCID: PMC3720066.
8: Bestetti F. Valutazione clinica del cinnoxicam 30 mg in pazienti affetti da osteoartrosi. Studio controllato in doppio cieco [Clinical evaluation of cinnoxicam 30 mg in patients with osteoarthrosis. A double-blind controlled study]. Minerva Med. 1996 Mar;87(3):117-22. Italian. PMID: 8668288.
9: Peretti G. Valutazione clinica del cinnoxicam 30 mg in pazienti affetti da osteoartrosi. Studio controllato in doppio cieco [Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial]. Minerva Med. 1996 Apr;87(4):155-60. Italian. PMID: 8700339.
10: Mangano NG, Sabella P, Mangano A. Effetti "in vitro" della L-Carnitina sulla inibizione della motilità degli spermatozoi indotta da F.A.N.S [In vitro effects of L-carnitine on the inhibition of sperm mobility induced by FANS]. Clin Ter. 2000 May-Jun;151(3):173-6. Italian. PMID: 10958050.
